Roche Accutane “Fallback” Risk Plan May Test FDA Authority Over Registries
Executive Summary
Risk management concerns over Roche's Accutane could re-open the issue of whether FDA can require patient registries and limited distribution programs
You may also be interested in...
Accutane Legislation Planned; Rep. Stupak Wants Mandatory Registries
Rep. Bart Stupak (D-Mich.) is drafting legislation to mandate patient and prescriber registries for the acne drug Accutane
Accutane Legislation Planned; Rep. Stupak Wants Mandatory Registries
Rep. Bart Stupak (D-Mich.) is drafting legislation to mandate patient and prescriber registries for the acne drug Accutane
Accutane Risk Management Program Will Be Subject Of FDA Committee
FDA plans to convene an advisory committee this winter to assess the risk management program designed to prevent birth defects associated with Roche's acne therapy Accutane (isotretinoin)